David A. Siegel Vir Biotechnology, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 42,800 shares of VIR stock, worth $316,720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,800
Previous 73,500
41.77%
Holding current value
$316,720
Previous $654,000
51.07%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VIR
# of Institutions
218Shares Held
87MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$123 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$122 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$97.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$41.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$26.4 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $982M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...